Chemotherapeutic management of stage IV non-small cell lung cancer.
about
A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancerIs the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?[Vinorelbine plus oxaliplatin versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: a systematic review].Lung cancer: current diagnosis and treatmentFactors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer.Laser surgery of early glottic cancer in elderlyPARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerHead and neck cancer in the elderly: a retrospective study over 10 years (1999 - 2008).Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinomaNorthampton outcome for first and second line chemotherapy in non-small cell lung cancer: 5 years data.Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathwaysA new PET/CT volumetric prognostic index for non-small cell lung cancerPrognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer.Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry.Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients.Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCERIdentifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland.Health state utilities for non small cell lung cancer.Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patientsVariations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience.Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.Radiation therapy is well tolerated and produces excellent control rates in elderly patients with locally advanced head and neck cancers.Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unitCell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy.Health-related quality of life in lung cancer patients in Serbia: correlation with socio-economic and clinical parameters.Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV.Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer.Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.Microvascular head and neck reconstruction in the elderly: The University of Brescia experience.
P2860
Q26865662-32E7299D-4596-4CEC-B360-2205F68AB693Q27006021-924AEF79-EFFB-4504-9F13-B13AAEAE9F01Q30830928-2D267951-A2BA-44DB-943E-B86327B5DC20Q33391097-A8C12FE7-DFBA-4B50-99E1-BDDB5A23FDDDQ33554085-0970F0D6-7FE2-4ACD-A382-F964DA059360Q33600434-5F4CA683-3C15-451D-8075-E3B1DB9DDFA6Q33704656-09A34A50-C2DB-4581-A609-95D9E1263EAEQ33799085-6AB4D47C-EB27-4C9C-BE8E-9006A00883B0Q34041708-38C1975D-3BBA-4B1D-B93D-59AE6A584C7CQ34220677-350A5B36-143A-412B-BFBA-16A7F5800E38Q34450520-2AFC41A1-8950-407A-97FD-16D006BCCDB5Q34487100-A8C4BE73-D957-49D2-8ECD-CE8C03F047ECQ34780183-FF6291C6-046A-465B-92FC-CDA39735BF18Q35173372-CD652EEC-DD6F-4C8C-B3E8-26973BCF3441Q35688617-37BA04F2-47D1-4E4E-A7BE-EFDCE2F05224Q35763231-42522826-EC4F-42B3-A37D-D778D2FEC922Q35835931-31B8A9E8-5ADB-4EC3-8785-0E6151C076C1Q35864613-1626D999-27DA-41C2-B16F-2615FD5F9DB9Q36412597-CCBC27A6-B9C6-4711-B906-2D9EDFEFF087Q36490370-D30993AC-E49C-43B7-B5A3-7D98AFF2E393Q36609433-A5679F92-00A0-4BFF-A915-D6BA307F60F8Q36654677-B74C07DD-ACDA-4FCB-A0FB-B6C9F155E56EQ36862865-EE6F1FBE-746E-4B27-9737-8A330554B30CQ36942514-ABD39BD4-AB5F-4D7F-A2C9-2F80057266B5Q36963976-00391B8A-77F7-426E-9A81-8234F8895449Q37102914-22006F1E-5382-4FA5-A4F0-CB73631034BEQ37117859-5F9E8060-4788-4CBF-835E-A652975980ADQ37177238-F2E835B8-59AF-4BE5-B066-BFDE08DED63EQ37290704-E3696204-10C6-4CF0-BACC-3D20F68BF39CQ37421934-B188B7EE-2000-4D70-BC62-B59BE25A022BQ37732287-D0F8A3EB-D414-4387-8331-80F6B468F599Q37945643-5E4808B2-B1C5-40AF-B162-5797DE7263FDQ38014317-2E14A764-5911-4646-A374-ED0EE3F51789Q38619020-DD777E99-D3AF-47BE-BBE5-791B30AAAB0EQ41157591-28F42D00-D185-4FF1-ADB3-9E6E1F3C622EQ43548278-783D6FE4-F0FB-42E6-8AD5-0023E3CE3C55Q45794846-9D68EC25-3F5D-4B92-9383-87D2CB9DFC69Q46789949-7CB89FDF-A9FF-44F6-9062-04588767B85CQ47610558-6CB516AF-9FA9-4267-ADB6-9FA4F70C30DAQ47966090-859FED50-D6FF-4F2A-8F79-720DBF11E762
P2860
Chemotherapeutic management of stage IV non-small cell lung cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Chemotherapeutic management of stage IV non-small cell lung cancer.
@en
type
label
Chemotherapeutic management of stage IV non-small cell lung cancer.
@en
prefLabel
Chemotherapeutic management of stage IV non-small cell lung cancer.
@en
P2093
P1433
P1476
Chemotherapeutic management of stage IV non-small cell lung cancer.
@en
P2093
David E Morris
Gregory A Masters
Mark A Socinski
Rogerio Lilenbaum
P304
P356
10.1378/CHEST.123.1_SUPPL.226S
P407
P433
P577
2003-01-01T00:00:00Z